drugset / Trial / NCT05130827
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Phase 2
Active not recruiting
17 enrolled
Memorial Sloan Kettering Cancer Center
BeyondSpring Pharmaceuticals Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will see how long it takes for white blood cell counts to return to normal in people with multiple myeloma (MM) who receive plinabulin and pegfilgrastim after undergoing an autologous hematopoietic stem cell transplant (AHCT).
Timeline
- Start
- 2021-12-21
- Primary completion
- 2026-11
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plinabulin | Small molecule | 40 mg | Intravenous |